F16.150
Hallucinogen abuse with hallucinogen-induced psychotic disorder with delusions
Clinical Classification Guidelines
Medical Intelligence & Overview
ICD-10 code F16.150 refers to a condition where an individual misuses hallucinogenic substances, leading to a psychotic disorder characterized by hallucinations and delusions. This condition often develops after the use of substances like LSD, psilocybin, or peyote. Recognizing this disorder is crucial for timely intervention and appropriate treatment, aiming to manage symptoms and address substance abuse issues.
Causes & Symptoms
Clinical Causes: Repeated consumption of hallucinogenic substances such as LSD, psilocybin mushrooms, peyote, or mescaline. Genetic predisposition to mental health disorders, which may increase susceptibility to psychotic episodes after drug use. Underlying psychiatric conditions, like schizophrenia or bipolar disorder, that can be exacerbated by hallucinogenic substances. Environmental stressors or traumatic events concurrent with substance use.
Key Symptoms: Persistent or recurrent hallucinations that involve seeing, hearing, or feeling things that aren't present. Delusional beliefs that are fixed and false, such as paranoid or grandiose ideas. Disorganized thinking, leading to confused speech and inability to concentrate. Altered perception of reality, including distorted sensory experiences. Anxiety, agitation, or paranoia about surroundings or others. Potential mood disturbances, such as depression or euphoria during episodes. Possible physical symptoms like dilated pupils, increased heart rate, or nausea during active drug effects.
Diagnostic & Treatment
Diagnosis Path: Diagnosis involves a comprehensive clinical assessment, including a detailed history of substance use and mental health. Healthcare professionals utilize psychiatric evaluation tools to identify psychotic symptoms and confirm that they're associated with hallucinogen use. Laboratory tests may support the diagnosis by detecting recent drug exposure. Differential diagnosis rules out other causes of psychosis, such as primary psychiatric disorders or medical conditions.
Treatment Protocols: Hospitalization may be necessary during acute episodes to ensure safety and provide intensive care. Psychotropic medications, such as antipsychotics, are prescribed to reduce hallucinations and delusions. Psychological therapies, including cognitive-behavioral therapy (CBT), help patients understand their condition, develop coping strategies, and prevent relapse. Substance abuse counseling and support groups aim to reduce or stop hallucinogen use. Treatment of any co-occurring mental health disorders that may complicate recovery. Monitoring and follow-up to assess progress and adjust treatment plans.
Clinical Advice & FAQs
Billing Guidance
Is F16.150 a billable ICD-10 code?
Yes, F16.150 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report F16.150?
Clinical documentation must specify the nature of Hallucinogen abuse with hallucinogen-induced psychotic disorder with delusions and any associated comorbidities for accurate reporting.
Cite this Clinical Reference